Related Experiment Video
Updated: May 7, 2026

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas
Published on: September 13, 2019
Attacking cancer at its root
1Abramson Family Cancer Research Institute, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA. craig@mail.med.upenn.edu
Abstract:
This year the Lasker DeBakey Clinical Research Award will be shared by Brian Druker, Nicholas Lydon, and Charles Sawyers for their development of a targeted molecular therapy for treating chronic myeloid leukemia. Their work demonstrated the ability of drugs directed against cancer-causing oncogenes to turn a rapidly fatal malignancy into a manageable chronic disease.
Insights
Brian Druker, Nicholas Lydon, and Charles Sawyers developed targeted molecular therapy for chronic myeloid leukemia. This breakthrough transformed a fatal cancer into a manageable chronic condition.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Chronic myeloid leukemia (CML) was historically a rapidly fatal hematologic malignancy.
- The identification of the Philadelphia chromosome and its BCR-ABL oncogene provided a molecular target for therapy.
Discussion:
- Targeted molecular therapies, specifically tyrosine kinase inhibitors (TKIs), were developed to inhibit the BCR-ABL oncogene.
- These therapies demonstrated unprecedented efficacy in CML treatment.
Key Insights:
- The development of targeted therapies against cancer-causing oncogenes represents a paradigm shift in cancer treatment.
- This approach effectively converts fatal malignancies into manageable chronic diseases, significantly improving patient survival and quality of life.
- The work of Druker, Lydon, and Sawyers exemplifies precision medicine in action.
Outlook:
- Continued research into targeted therapies for other cancers.
- Potential for similar therapeutic strategies to manage other oncogene-driven malignancies.
- Advancements in drug development and personalized medicine hold promise for future cancer care.
Related Concept Videos
Cancer
What is Cancer?
Although people have known about cancer for centuries, it was only in 1761 that Giovanni Morgagni of Padua performed a detailed autopsy of patients who died from...
Cancers Originate from Somatic Mutations in a Single Cell
Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Cancers Originate from Somatic Mutations in a Single Cell
Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...

